ConvaTec Group PLC 27.5% potential upside indicated by Berenberg Bank

Broker Ratings

ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 27.5% according to Berenberg Bank.

CTEC.L

Berenberg Bank set a target price of 310 GBX for the company, which when compared to the ConvaTec Group PLC share price of 243 GBX at opening today (21/06/2024) indicates a potential upside of 27.5%. Trading has ranged between 195 (52 week low) and 295 (52 week high) with an average of 5,128,038 shares exchanging hands daily. The market capitalisation at the time of writing is £4,964,178,250.

Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Advanced Wound Care includes advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories, and personalized services for individuals with a stoma. Continence and Critical Care includes products and services for people with urinary continence issues related to spinal cord injuries and other causes. Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.



Share on:

Latest Company News

Convatec names former Fortrea CFO Jill McConnell as successor to Fiona Ryder

Convatec has appointed Jill McConnell as its next Chief Financial Officer, with the appointment taking effect on 1 March...

Convatec appoints Jens Viebke as Non-Executive Director

Convatec has appointed Dr Jens Viebke as a Non-Executive Director with immediate effect and added him to the Remuneration...

Convatec names NED and outlines CFO transition

Convatec has outlined finance leadership changes, appointed Tobias Hestler as a Non-Executive Director and reaffirmed its 2026 expectations....

Convatec sets out ‘Accelerate’ strategy to drive faster sustainable growth

Convatec has introduced its new Accelerate strategy, outlining four strategic pillars and reaffirming medium-term guidance including 6–8% annual organic...

Convatec reports 6.5% revenue growth and upgraded medium-term target

Convatec Group PLC reported FY2025 revenue of $2.44bn, up 6.5% on a reported basis, with adjusted operating profit rising...

Convatec Group Plc launches $300m share buyback programme

Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The...

    Search